Investment Securities

9 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Investment Securities

NOTE 10. INVESTMENT SECURITIES

As of the quarter ending September 30, 2012 the Company reclassified 66,667 ( retroactively adjusted for reverse stock split.) common shares of Entest Biomedical, Inc. as Securities Available for Sale from Securities Accounted for under the Equity Method. 

On September 28, 2015 Zander Theraputics, Inc. caused to be issued to Regen Biopharma, Inc. 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to Regen Biopharma, Inc. by Zander Theraputics, Inc as a license initiation fee.

As of September 30, 2015 the Company recognized an other than temporary impairment of $41,333,361 on 8,066,667 Common Shares of Entest Biomedical, Inc.

The Company concluded that such impairment should be recognized based primarily due to:

(a) History of recurring losses for Entest Biomedical, Inc.

(b) Large percentage decline in fair value during the Company’s period of ownership

The common shares of Entest Biomedical, Inc described above constitute the Company’s sole investment securities as of June 30, 2016.

8,066,667	Common Shares of Entest Biomedical, Inc.
Basis		Fair Value	Total Unrealized Losses in Other Comprehensive Income		Net Unrealized Gain or (Loss )realized during the quarter  ended June 30, 2016
195,000		80,667	(114,333	)	23,393